Biotech | March 20, 2024
Lonza to buy US biologics site from Roche for US$ 1.2 billion
Lonza plans to invest approximately CHF 500 million to upgrade the facility
Lonza plans to invest approximately CHF 500 million to upgrade the facility
The plan essentially was to separate Aster’s India and GCC businesses to unlock long-term value
Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older
Additional capacity broadens Grace’s fine chemical capabilities for API production
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ II, India
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
Christoph Funke's extensive career includes leadership roles at organizations such as Fresenius Kabi and Strides Pharma Science
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
The first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer
Both organisations enter into a long- term collaboration to expand patient access in India
Subscribe To Our Newsletter & Stay Updated
